PurposeTo evaluate the efficacy of hydromorphone-OROS (HM-OROS) in reducing sleep disturbanceand relieving cancer pain. Materials and MethodsOne hundred twenty cancer patients with pain (numeric rating scale [NRS] ≥ 4) and sleepdisturbance (NRS ≥...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A101596257
2014
-
KCI등재,SCIE,SCOPUS
학술저널
331-338(8쪽)
6
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
PurposeTo evaluate the efficacy of hydromorphone-OROS (HM-OROS) in reducing sleep disturbanceand relieving cancer pain. Materials and MethodsOne hundred twenty cancer patients with pain (numeric rating scale [NRS] ≥ 4) and sleepdisturbance (NRS ≥...
PurposeTo evaluate the efficacy of hydromorphone-OROS (HM-OROS) in reducing sleep disturbanceand relieving cancer pain.
Materials and MethodsOne hundred twenty cancer patients with pain (numeric rating scale [NRS] ≥ 4) and sleepdisturbance (NRS ≥ 4) were evaluated. The initial HM-OROS dosing was based on previousopioid dose (HM-OROS:oral morphine=1:5). Dose adjustment of the study drug waspermitted at the investigator’s discretion. Pain intensity, number of breakthrough painepisodes, and quality of sleep were evaluated.
ResultsA total of 120 patients received at least one dose of HM-OROS; 74 of them completed thefinal assessment. Compared to the previous opioids, HM-OROS reduced the average painNRS from 5.3 to 4.1 (p < 0.01), worst pain NRS from 6.7 to 5.4 (p < 0.01), sleep disturbanceNRS from 5.9 to 4.1 (p < 0.01), incidence of breakthrough pain at night from 2.63 to 1.53times (p < 0.001), and immediate-release opioids use for the management of breakthroughpain from 0.83 to 0.39 times per night (p = 0.001). Of the 74 patients who completed thetreatment, 83.7% indicated that they preferred HM-OROS to the previous medication. Theadverse events (AEs) were somnolence, asthenia, constipation, dizziness, and nausea.
ConclusionHM-OROS was efficacious in reducing cancer pain and associated sleep disturbances. TheAEs were manageable.
참고문헌 (Reference)
1 Lawlor P, "ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study" 72 : 79-85, 1997
2 Gardner-Nix J, "The role of OROS hydromorphone in the management of cancer pain" 10 : 72-77, 2010
3 Oechsle K, "Symptom burden in palliative care patients: perspectives of patients, their family caregivers, and their attending physicians" 21 : 1955-1962, 2013
4 Vena C, "Sleep-wake disturbances in people with cancer part I: an overview of sleep, sleep regulation, and effects of disease and treatment" 31 : 735-746, 2004
5 Gibbins J, "Sleep-wake disturbances in patients with advanced cancer and their family carers" 38 : 860-870, 2009
6 Sela RA, "Sleep disturbances in palliative cancer patients attending a pain and symptom control clinic" 3 : 23-31, 2005
7 Kvale EA, "Sleep disturbance in supportive care of cancer: a review" 9 : 437-450, 2006
8 Hearson B, "Sleep disturbance in patients with advanced cancer" 14 : 30-37, 2008
9 Mercadante S, "Sleep disorders in advanced cancer patients: prevalence and factors associated" 12 : 355-359, 2004
10 Nalamachu SR, "Safety and Tolerability of Once-Daily OROS((R)) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies" 44 : 852-865, 2012
1 Lawlor P, "ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study" 72 : 79-85, 1997
2 Gardner-Nix J, "The role of OROS hydromorphone in the management of cancer pain" 10 : 72-77, 2010
3 Oechsle K, "Symptom burden in palliative care patients: perspectives of patients, their family caregivers, and their attending physicians" 21 : 1955-1962, 2013
4 Vena C, "Sleep-wake disturbances in people with cancer part I: an overview of sleep, sleep regulation, and effects of disease and treatment" 31 : 735-746, 2004
5 Gibbins J, "Sleep-wake disturbances in patients with advanced cancer and their family carers" 38 : 860-870, 2009
6 Sela RA, "Sleep disturbances in palliative cancer patients attending a pain and symptom control clinic" 3 : 23-31, 2005
7 Kvale EA, "Sleep disturbance in supportive care of cancer: a review" 9 : 437-450, 2006
8 Hearson B, "Sleep disturbance in patients with advanced cancer" 14 : 30-37, 2008
9 Mercadante S, "Sleep disorders in advanced cancer patients: prevalence and factors associated" 12 : 355-359, 2004
10 Nalamachu SR, "Safety and Tolerability of Once-Daily OROS((R)) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies" 44 : 852-865, 2012
11 Graci G, "Pathogenesis and management of cancer-related insomnia" 3 : 349-359, 2005
12 Mercadante S, "Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit" 21 : 1853-1859, 2013
13 Wallace M, "Once-daily OROS hydromorphone for the management of chronic nonmalignant pain : a dose-conversion and titration study" 61 : 1671-1676, 2007
14 Yamaguchi T, "Japanese Society of Palliative Medicine. Clinical guideline for pharmacological management of cancer pain: the Japanese Society of Palliative Medicine recommendations" 43 : 896-909, 2013
15 Mystakidou K, "How is sleep quality affected by the psychological and symptom distress of advanced cancer patients?" 23 : 46-53, 2009
16 Carney S, "Differences in sleep disturbance parameters between oncology outpatients and their family caregivers" 29 : 1001-1006, 2011
17 Yun YH, "Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory" 66 : 439-444, 2004
18 Stepanovic A, "Clinical efficacy of OROS(R) hydromorphone in patients suffering from severe chronic pain: A Study undertaken in routine clinical practice" 123 : 531-535, 2011
19 Coyle N, "Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life" 5 : 83-93, 1990
20 Akechi T, "Associated and predictive factors of sleep disturbance in advanced cancer patients" 16 : 888-894, 2007
21 Hanna M, "An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain" 8 : 14-, 2009
22 Bruera E, "A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group" 14 : 1713-1717, 1996
23 Hanna M, "118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain" 7 : 17-, 2008
Bladder and Liver Involvement of Visceral Larva Migrans May Mimic Malignancy
학술지 이력
연월일 | 이력구분 | 이력상세 | 등재구분 |
---|---|---|---|
2024 | 평가예정 | 해외DB학술지평가 신청대상 (해외등재 학술지 평가) | |
2021-01-01 | 평가 | 등재학술지 선정 (해외등재 학술지 평가) | |
2020-12-01 | 평가 | 등재후보로 하락 (해외등재 학술지 평가) | |
2010-01-01 | 평가 | 등재학술지 유지 (등재유지) | |
2008-01-01 | 평가 | 등재학술지 유지 (등재유지) | |
2005-05-27 | 학술지명변경 | 한글명 : 대한암학회지 -> Cancer Research and Treatment | |
2005-01-01 | 평가 | 등재학술지 선정 (등재후보2차) | |
2004-01-01 | 평가 | 등재후보 1차 PASS (등재후보1차) | |
2002-01-01 | 평가 | 등재후보학술지 선정 (신규평가) |
학술지 인용정보
기준연도 | WOS-KCI 통합IF(2년) | KCIF(2년) | KCIF(3년) |
---|---|---|---|
2016 | 3.58 | 0.89 | 3.01 |
KCIF(4년) | KCIF(5년) | 중심성지수(3년) | 즉시성지수 |
2.62 | 2.28 | 1.846 | 0.26 |